Technology | Nuclear Imaging | June 09, 2016

Siemens Healthineers Debuts Mobile PET/CT System, Molecular Imaging Software at SNMMI ‘16

Latest version of syngo.via for Molecular Imaging adds SPECT capabilities; Biograph Horizon PET/CT now has mobile configuration

Siemens Healthineers, SNMMI '16, molecular imaging, syngo.via, Biograph Horizon PET/CT, mobile configuration

June 9, 2016 — At the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Siemens Healthineers will highlight a new release of its syngo.via for Molecular Imaging software. The company will also feature a new mobile configuration of its Biograph Horizon positron emission tomography/computed tomography (PET/CT) system at the meeting, June 11-15 in San Diego.

The new version of the syngo.via for Molecular Imaging software enables preprocessing, reading and reporting for PET and, for the first time, single photon emission computed tomography (SPECT). This enables physicians to use the intuitive user interface to allow for synergies across departments.

The new iteration of syngo.via for Molecular Imaging offers four new features. For SPECT, organ processing for nuclear medicine helps physicians visualize and quantify the physiological characteristics of organs such as the lungs, kidneys and stomach. For PET, the Molecular Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) features together enable physicians to measure the standardized metabolic activity of the entire tumor mass, potentially improving the preoperative identification of high-risk patients and the prognostic value in predicting overall survival. Hybrid gating 4-D visualization of PET and CT supports therapy planning and delivery.

And syngo.via MI Workplace – the company’s cost-effective, scalable configuration of syngo.via for Molecular Imaging – is designed to bolster the performance of PET and SPECT scanners. In addition to image processing, syngo.via MI Workplace may increase diagnostic confidence by quantifying disease parameters in a wide range of clinical areas. Available with the Biograph Horizon PET/CT system and with all Symbia SPECT and SPECT/CT systems, syngo.via MI Workplace may increase a facility’s clinical capabilities and can be expanded to accommodate an ever-evolving exam mix.

Siemens Healthineers also debuts the mobile configuration of its recently introduced Biograph Horizon PET/CT system, which delivers high-end functionality at an attractive total cost of ownership. This new mobile-ready version of Biograph Horizon is intended for cost-conscious healthcare facilities that do not yet possess the patient volume to support installation of a fixed PET/CT. The mobile configuration also may be ideal for consolidated health systems looking to tailor their imaging delivery strategy in diverse service areas.

Migrating technology from the company’s premium Biograph family of PET/CT systems to help providers address more clinical indications in oncology, neurology and cardiology while also introducing new efficiencies and cost savings, Biograph Horizon enables physicians to visualize small lesions early. The system’s 4 mm lutetium orthosilicate (LSO) crystals scintillate faster and boast a higher light output than commonly used bismuth germanate oxide (BGO) crystals, yielding high image resolution and better image quality as well as enabling Time-of-Flight acquisition. By receiving more detailed patient data earlier, clinicians may stage disease and evaluate therapy response more accurately, contributing to more effective care pathways.

With the addition of the mobile version of Biograph Horizon, the entire line of Biograph PET/CT systems from Siemens Healthineers – including Biograph mCT and Biograph mCT Flow – is available in mobile as well as fixed configurations.

For more information:

Related Content

CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging | September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging | June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging | January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging | December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
Overlay Init